FDA Grants Approval for Brivaracetam ANDA219766 by Shandong
The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 219766 for Brivaracetam submitted by Shandong.
Published: July 18, 2026
Updated: July 18, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Antiepileptic
Asset: Shandong
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Shandong
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Shandong's generic Brivaracetam introduces significant competition in the antiepileptic market. This could pressure pricing and market share for existing branded products, necessitating strategic adjustments from portfolio teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies from Shandong and competitors.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.